Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Ji Yun Lee, Soo-Mee Bang, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Lee Gyeong-Won, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Je-Jung Lee, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Min Kyoung Kim

Blood (2022) 140 (Supplement 1): 12501–12502.

https://doi.org/10.1182/blood-2022-165807

Published: 2022

Journal Articles

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9498–9500.

https://doi.org/10.1182/blood-2022-165716

Published: 2022

Journal Articles

Real-World Treatment Patterns and Outcomes of Patients with Newly Diagnosed Multiple Myeloma: An Analysis Using National Health Insurance Service Database

YooSun Lee, Junghyun Yoon, Boyoung Park, Hyeon-Seok Eom

Blood (2022) 140 (Supplement 1): 5156–5157.

https://doi.org/10.1182/blood-2022-157676

Published: 2022

Journal Articles

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Yuqin Song, Won-Seog Kim, Dok-Hyun Yoon, Haiyan Yang, Junning Cao, Dongmei Ji, Youngil Koh, Hongmei Jing, Hyeon-Seok Eom, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Jie Jin, Mei Wang, Jingrun Li, Jun Zhu

Blood (2022) 140 (Supplement 1): 6545–6546.

https://doi.org/10.1182/blood-2022-162947

Published: 2022

Journal Articles

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Won-Seog Kim, Dok-Hyun Yoon, MD PhD, Hyeon-Seok Eom, Youngil Koh, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Yuqin Song, MD PhD, Haiyan Yang, MD PhD, Mei Wang, Jingrun Li, MDPhD, Xubin Huang, Xueyuan Deng, Kan Chen, Zhenfan Yang, Jun Zhu

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-134650

Published: 2020

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

Jin Roh, Hyungwoo Cho, MD, Dok Hyun Yoon, Jung Yong Hong, A-Neum Lee, Hyeon-Seok Eom, Hyewon Lee, MD, Weon Seo Park, Jae Ho Han, MD, Seong Hyun Jeong, Joon Seong Park, MD, Hyo-Kyung Pak, So-Woon Kim, MD, Sang-Yeob Kim, Cheolwon Suh, Jooryung Huh, Chan-Sik Park

Blood (2019) 134 (Supplement_1): 2901.

https://doi.org/10.1182/blood-2019-130279

Published: 2019

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Ho-Young Yhim, MD, Cheolwon Suh, Seok Jin Kim, MD PhD, Deok-Hwan Yang, MD PhD, Hyeon-Seok Eom, MD, Kyoung Ha Kim, MD PhD, Yong Park, Jin Seok Kim, MD PhD, Hyo Jung Kim, MD PhD, Dok Hyun Yoon, MD PhD, Won Seog Kim, MD PhD, Jae-Yong Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 4076.

https://doi.org/10.1182/blood-2019-122631

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study

Won-Seog Kim, Hyeon-Seok Eom, Su-Peng Yeh, MD, Seok-Goo Cho, MD PhD, Dae Seog Heo, MD, Jin Seok Kim, MD PhD, Ming Yao, MD, Jun Zhu, Grace Gao, Lijia Zhang, Ming Qi, MD PhD, Huiqiang Huang, Yok Lam Kwong, MD FRCP

Blood (2018) 132 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2018-99-111885

Published: 2018

Journal Articles

High Level of Pre-Treatment C-Reactive Protein-to-Albumin Ratio Predicts Inferior Prognosis in Diffuse Large B Cell Lymphoma

Jongheon Jung, Eunyoung Lee, Weon Seo Park, Ju-Hyun Park, Hyeon-Seok Eom, Hyewon Lee, MD

Blood (2018) 132 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2018-99-116205

Published: 2018

Journal Articles

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

Silvia Park, Seok Jin Kim, MD PhD, Jung Yong Hong, Dok Hyun Yoon, MD PhD, Jin Seok Kim, MD PhD, Hye Jin Kang, MD PhD, Hyeon-Seok Eom, Mark Hong Lee, Cheolwon Suh, MD PhD, Won Seog Kim, MD, Ph. D.

Blood (2017) 130 (Supplement 1): 4077.

https://doi.org/10.1182/blood.V130.Suppl_1.4077.4077

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia

Sang-A Kim, MD, Sung-Soo Yoon, MD PhD, Youngil Koh, MD, Dong-Yeop Shin, MDPhD, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD, Hyeon-Seok Eom, Je-Jung Lee, MD PhD, Jeong-Ok Lee, MD, Soo-Mee Bang, MDPhD

Blood (2017) 130 (Supplement 1): 1814.

https://doi.org/10.1182/blood.V130.Suppl_1.1814.1814

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2017) 130 (Supplement 1): 4088.

https://doi.org/10.1182/blood.V130.Suppl_1.4088.4088

Published: 2017

NARROW

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

A Multicenter Prospective Study for Validation of the Korean Simple Geriatric Assessment Tool in Elderly Patients with Multiple Myeloma

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Real-World Treatment Patterns and Outcomes of Patients with Newly Diagnosed Multiple Myeloma: An Analysis Using National Health Insurance Service Database

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study

High Level of Pre-Treatment C-Reactive Protein-to-Albumin Ratio Predicts Inferior Prognosis in Diffuse Large B Cell Lymphoma

A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia

Unmet Needs for a Better Treatment in Patients with Peripheral T Cell Lymphoma: Data from a Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only